These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 25793168)

  • 1. Is non-biological treatment of rheumatoid arthritis as good as biologics?
    Parida JR; Misra DP; Wakhlu A; Agarwal V
    World J Orthop; 2015 Mar; 6(2):278-83. PubMed ID: 25793168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Maxwell LJ; Buchbinder R; Lopez-Olivo MA; Suarez-Almazor ME; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012591. PubMed ID: 28282491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis.
    Doan QV; Chiou CF; Dubois RW
    J Manag Care Pharm; 2006 Sep; 12(7):555-69. PubMed ID: 16981801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
    Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
    Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Mudano AS; Tanjong Ghogomu E; Suarez-Almazor ME; Buchbinder R; Maxwell LJ; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012657. PubMed ID: 28481462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).
    Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012437. PubMed ID: 27855242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of synthetic drugs in the biologic era: therapeutic strategies for treating juvenile idiopathic arthritis.
    Hügle B; Horneff G
    Expert Opin Pharmacother; 2016; 17(5):703-14. PubMed ID: 26678914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort.
    Lukas C; Mary J; Debandt M; Daïen C; Morel J; Cantagrel A; Fautrel B; Combe B
    Arthritis Res Ther; 2019 Nov; 21(1):243. PubMed ID: 31730497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating to target in established rheumatoid arthritis: Challenges and opportunities in an era of novel targeted therapies and biosimilars.
    Woodworth TG; den Broeder AA
    Best Pract Res Clin Rheumatol; 2015; 29(4-5):543-9. PubMed ID: 26697765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second-line therapy with biological drugs in rheumatoid arthritis patients in German rheumatologist practices: a retrospective database analysis.
    Gossen N; Jacob L; Kostev K
    Rheumatol Int; 2016 Aug; 36(8):1113-8. PubMed ID: 26936261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
    Smolen JS; Landewé RBM; Bijlsma JWJ; Burmester GR; Dougados M; Kerschbaumer A; McInnes IB; Sepriano A; van Vollenhoven RF; de Wit M; Aletaha D; Aringer M; Askling J; Balsa A; Boers M; den Broeder AA; Buch MH; Buttgereit F; Caporali R; Cardiel MH; De Cock D; Codreanu C; Cutolo M; Edwards CJ; van Eijk-Hustings Y; Emery P; Finckh A; Gossec L; Gottenberg JE; Hetland ML; Huizinga TWJ; Koloumas M; Li Z; Mariette X; Müller-Ladner U; Mysler EF; da Silva JAP; Poór G; Pope JE; Rubbert-Roth A; Ruyssen-Witrand A; Saag KG; Strangfeld A; Takeuchi T; Voshaar M; Westhovens R; van der Heijde D
    Ann Rheum Dis; 2020 Jun; 79(6):685-699. PubMed ID: 31969328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational use of new and existing disease-modifying agents in rheumatoid arthritis.
    Kremer JM
    Ann Intern Med; 2001 Apr; 134(8):695-706. PubMed ID: 11304108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug combinations with methotrexate to treat rheumatoid arthritis.
    Rath T; Rubbert A
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S52-7. PubMed ID: 21044434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis.
    Hazlewood GS; Barnabe C; Tomlinson G; Marshall D; Devoe D; Bombardier C
    BMJ; 2016 Apr; 353():i1777. PubMed ID: 27102806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy of biological agents in methotrexate-refractory rheumatoid arthritis patients: a Bayesian mixed treatment comparison.
    Choi M; Hyun MK; Choi S; Tchoe HJ; Lee SY; Son KM; Kim MJ; Jung YO; Kim HA
    Korean J Intern Med; 2017 May; 32(3):536-547. PubMed ID: 27253239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Inhibition of radiographic progression in rheumatoid arthritis by anti-rheumatic drugs (DMARDs)].
    Suzuki Y; Wakabayashi T; Saito E; Suwa A
    Clin Calcium; 2007 Apr; 17(4):546-52. PubMed ID: 17404484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
    Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monotherapy in rheumatoid arthritis.
    Scher JU
    Bull Hosp Jt Dis (2013); 2013; 71(3):204-7. PubMed ID: 24151946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remission in rheumatoid arthritis: wishful thinking or clinical reality?
    Sesin CA; Bingham CO
    Semin Arthritis Rheum; 2005 Dec; 35(3):185-96. PubMed ID: 16325659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leflunomide is equally efficacious and safe compared to low dose rituximab in refractory rheumatoid arthritis given in combination with methotrexate: results from a randomized double blind controlled clinical trial.
    Wijesinghe H; Galappatthy P; de Silva R; Seneviratne SL; Saravanamuttu U; Udagama P; Hart M; Kelleher P; Senerath U; Fernandopulle R; Weerasekera LP; Wijayaratne LS
    BMC Musculoskelet Disord; 2017 Jul; 18(1):310. PubMed ID: 28724365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.